Calaspargase-Pegol-Mknl Combined with BCL-2 and MCL-1 Inhibition for Acute Myeloid Leukemia
Dominique Bollino, Xinrong Ma, Kayla M. Tighe, Andrea Casildo, Katharina Richard, Antonino Passaniti, Brandon Carter-Cooper, Erin T. Strovel, Ashkan Emadi · 2024
Read Calaspargase-Pegol-Mknl Combined with BCL-2 and MCL-1 Inhibition for Acute Myeloid Leukemia by Dominique Bollino, Xinrong Ma, Kayla M. Tighe, Andrea Casildo, Katharina Richard, Antonino Passaniti, Brandon Carter-Cooper, Erin T. Strovel, Ashkan Emadi (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11641566.txt.
Description
Dominique Bollino and co-authors test drug mixes against acute myeloid leukemia in a 2024 lab study. The cancer is a fast-growing blood disease. One drug in the mix, calaspargase pegol, is a long-acting enzyme that starves cancer cells of a food amino acid. Two partner drugs block proteins that keep cells alive, called BCL-2 and MCL-1. Blocking MCL-1 may beat a common route of drug escape.
Tests used human cancer cell lines, patient samples, and mice carrying human tumors. The enzyme drug made the BCL-2 blocker work harder against the cancer. It did not change the MCL-1 blocker's effect. The strong pair also slowed protein making inside cells. The authors back human trials of the enzyme drug with BCL-2 blocking.
Catalog record
| CREATOR | Dominique Bollino, Xinrong Ma, Kayla M. Tighe, Andrea Casildo, Katharina Richard, Antonino Passaniti, Brandon Carter-Cooper, Erin T. Strovel, Ashkan Emadi |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |